

Contents of *The American Journal of Psychiatry*

September 1996

Volume 153

Presidential Papers 1996

Presidential address: Leaders of reform: equity, quality, outcomes, and partnerships. <i>Mary Jane England</i>	1119
Response to the Presidential address: why we must prevail. <i>Harold I. Eist</i>	1123
Mary Jane England, MD, 124th President, 1995–1996. <i>Leah J. Dickstein</i>	1126

Editorial

Compared to attention deficit hyperactivity disorder . . . <i>Gabrielle A. Carlson</i>	1128
--	------

Images in Neuroscience

Neuroimaging, XII: SPECT imaging of dopamine nerve terminals. <i>Essay by John P. Seibyl, Ken Marek and Robert B. Innis</i>	1131
---	------

Special Article

Antidepressant treatment during breast-feeding. <i>Katherine L. Wisner, James M. Perel and Robert L. Findling</i>	1132
---	------

Regular Articles

Is maternal smoking during pregnancy a risk factor for attention deficit hyperactivity disorder in children? <i>Sharon Milberger, Joseph Biederman, Stephen V. Faraone, Lisa Chen and Janice Jones</i>	1138
Age-dependent decline of attention deficit hyperactivity disorder. <i>John C. Hill and Eugene P. Schoener</i>	1143
Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. <i>Timothy E. Wilens, Joseph Biederman, Jefferson Prince, Thomas J. Spencer, Stephen V. Faraone, Rebecca Warburton, David Schleifer, Meg Harding, Colleen Linehan and Daniel Geller</i>	1147
Backward-masking deficit in adolescents with schizophrenic disorders or attention deficit hyperactivity disorder. <i>Bjørn Rishovd Rund, Merete Øie and Kjetil Sundet</i>	1154
Association of abnormal smooth pursuit eye movements with the deficit syndrome in schizophrenic patients. <i>David E. Ross, Gunvant K. Thaker, Robert W. Buchanan, Adrienne C. Lahti, Deborah Medoff, John J. Bartko, Marianne Moran and Julie Hartley</i>	1158
Prenatal growth markers in schizophrenia: a monozygotic co-twin control study. <i>James O. Davis and H. Stefan Bracha</i>	1166
Anticipation in schizophrenia: new light on a controversial problem. <i>Philip Gorwood, Marion Leboyer, Bruno Falissard, Maurice Jay, Frédéric Rouillon and Josué Feingold</i>	1173
Sex differences in neuropsychological functioning among schizophrenic patients. <i>Richard R. J. Lewine, Elaine F. Walker, Rebecca Shurett, Jane Caudle and Catherine Haden</i>	1178
Suicidal behavior in schizophrenia and its relationship to awareness of illness. <i>Xavier F. Amador, Jill Harkavy Friedman, Chrysoula Kasapis, Scott A. Yale, Michael Flaum and Jack M. Gorman</i>	1185
Assessment of object relations and reality testing in methadone patients. <i>Megan J. Rutherford, John S. Cacciola, Arthur I. Alterman and James R. McKay</i>	1189
Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers. <i>Deborah S. Hasin, Kristin D. Trautman, Gloria M. Miele, Sharon Samet, Melissa Smith and Jean Endicott</i>	1195

Clinical Case Conference

Distinguishing borderline personality disorder from bipolar disorder: differential diagnosis and implications. <i>Sara Bolton and John G. Gunderson</i>	1202
---	------

Images in Psychiatry

Hilde Bruch, 1904–1984. <i>Essay by Stuart C. Yudofsky</i>	1208
--	------

Brief Reports

Association of monoamine oxidase A alleles with alcoholism among male Chinese in Taiwan. <i>Yun-Pung P. Hsu, El W. Loh, Wei J. Chen, Chiao-Chicy Chen, Jeng-Ming Yu and Andrew T. A. Cheng</i>	1209
MRI signal hyperintensities in geriatric depression. <i>Blaine S. Greenwald, Elisse Kramer-Ginsberg, K. Ranga Rama Krishnan, Manzar Ashtari, Peter M. Aupperle and Mahendra Patel</i>	1212
Alteration of brain dopamine and serotonin levels in cocaine users: a preliminary report. <i>Karley Y. Little, Umesh N. Patel, Thomas B. Clark and John D. Butts</i>	1216
Inositol treatment of obsessive-compulsive disorder. <i>Mendel Fux, Joseph Levine, Alex Aviv and R. H. Belmaker</i>	1219

The American Journal of Psychiatry is now on the Web! The *Journal's* home page features this month's table of contents, abstracts for every article, and full text of editorials, images in neuroscience, and images in psychiatry. Also featured is next month's table of contents, back issue abstracts, subscription information, and information for authors. You can access the *Journal's* home page at <http://www.appi.org/ajp>.

Psychiatry in New Zealand

On behalf of New Zealand client hospitals, we are seeking applications for the following full time posts:

Head, Department of Psychiatry
Consultant - Adult acute
Consultant - Child, Adolescent and Family
Consultant - Community Mental Health Service
Registrars (posts commence in Nov 96)

also, 6 and 12 month Locum posts in Community Mental Health.

Posts are available in both Islands, registration, immigration and relocation assistance may be provided. Recent changes to New Zealand's Medical Registration procedures will be discussed with appointable candidates.

Please fax curriculum vitae to:

New Zealand Medical Staffing Ltd,
fax +64-9-630 9622, ph +64-9-630 1769,
PO Box 74385 Market Road, Auckland,
New Zealand.

New Zealand Medical Staffing Ltd is a subsidiary of HealthLink New Zealand Group; New Zealand's largest provider of personnel to the Health Sector.



Recent Council Reports

CR43 *Psychiatric Services to Accident and Emergency Departments, £5.00*

CR44 *The Evidence of Children, £5.00*

CR45 *Statement on Reciprocity between the Royal College of Psychiatrists and the Royal Australian and New Zealand College of Psychiatrists, £5.00*

CR46 *Psychiatric Rehabilitation - Revised, £5.00*

Available from the Publications Department,
Royal College of Psychiatrists,
17 Belgrave Square, London SW1X 8PG
Tel. +44(0)171-235 2351, extension 146

Epilim Oral Prescribing Information

Presentation Epilim 200 Enteric Coated and Epilim 500 Enteric Coated: Enteric coated tablets containing 200mg, and 500mg Sodium Valproate Ph.Eur. respectively. Epilim Crushable Tablets containing 100mg Sodium Valproate Ph.Eur. Epilim Syrup and Epilim Liquid (sugar free) both containing 200mg Sodium Valproate Ph.Eur. per 5ml. Epilim Chrono 200, Epilim Chrono 300, and Epilim Chrono 500: Controlled release tablets containing a mixture of Sodium Valproate Ph.Eur. and Valproic Acid Fr.P. equivalent to 200mg, 300mg, and 500mg Sodium Valproate respectively. **Indications** Oral formulations of Epilim are indicated for all types of epilepsy. In women of child bearing age Epilim should be used only in severe cases or in those resistant to other treatment. **Dosage and administration** *Adults*; the dose should be titrated at three day intervals until seizure control is achieved. Initially 600mg a day increasing in steps of 200mg to a maximum dose of 2500mg per day. *Children over 20kg*; initially 400mg a day increasing in steps to a maximum dose of 35mg/kg/day. *Children under 20kg*; initially 20mg/kg/day - the dose may be increased in severe cases provided that plasma levels are monitored; above 40mg/kg/day chemistry and haematology should be monitored. Epilim Chrono may be given once or twice daily. All other formulations should be given twice daily. **Combination therapy**; levels of Epilim and co-administered anticonvulsants may be affected and optimum dosage is determined by seizure control. **Contraindications, Warnings, etc.** *Contraindications* Active liver disease, family history of severe liver disease, hypersensitivity to valproate. *Side effects* Impaired hepatic function, particularly in children, occasionally leading to hepatic failure - treatment should be withdrawn in patients who suddenly develop symptoms compatible with hepatic disease such as nausea, anorexia, jaundice or malaise. Hyperammonaemia with or without hepatic dysfunction. Blood dyscrasia - impaired platelet function, thrombocytopenia, occasional leucopenia and red cell hypoplasia. Occasionally increased appetite, weight gain, transient hair loss, behavioural disturbances, alterations to the menstrual cycle and pancreatitis. Symptoms of intoxication include ataxia, tremor, and stupor. **Drug interactions** Epilim has significant interactions with phenytoin, lamotrigine and other anticonvulsants. Epilim may potentiate the effects of neuroleptics, MAOIs and other antidepressants, anticoagulants and salicylates. Cimetidine may inhibit the metabolism of Epilim. Epilim has no effect on the efficacy of oral contraceptives. **Pregnancy** An increased incidence of congenital abnormalities has been demonstrated in offspring born to mothers with epilepsy both untreated and treated, including those treated with sodium valproate. Neural tube defects have been reported in about 1% of offspring of women who have received valproate during the first trimester of pregnancy. Pregnancies should be screened for neural tube defects by estimation of alpha-fetoprotein and ultrasound. Folate supplementation has been shown to reduce the incidence of neural tube defects in the offspring of high risk women. **Legal category** P.O.M. **Further information** Epilim is hygroscopic - tablets should not be removed from their foil until they are used. Epilim Chrono is recommended in cases where plasma valproate levels are being measured on account of its pharmacokinetics. The effective therapeutic range for valproate is 40-100mg/l (278-694 micromol/l). **Product Licence Numbers** Epilim 200 Enteric Coated 11723/0018, Epilim 500 Enteric Coated 11723/0020, Epilim 100mg Crushable Tablets 11723/0017, Epilim Syrup 11723/0025, Epilim Liquid 11723/0024, Epilim Chrono 200 11723/0078, Epilim Chrono 300 11723/0021, Epilim Chrono 500 11723/0079. **NHS Cost** Epilim 200 Enteric Coated 100 tablets £6.42, Epilim 500 Enteric Coated 100 tablets £16.04, Epilim 100mg Crushable Tablets 100 tablets £3.89, Epilim Syrup 300ml £5.89, Epilim Liquid 300ml £5.89, Epilim Chrono 200 100 tablets £7.70, Epilim Chrono 300 100 tablets £11.55, Epilim Chrono 500 100 tablets £19.25. **Address:** Sanofi Winthrop Ltd., One Onslow Street, Guildford, Surrey GU1 4YS. **Telephone:** (01483) 505515 **Fax:** (01483) 35432. Epilim, Epilim Chrono and the Chrono device are registered trade marks. **Date of preparation:** May 1996.

References:

1. Chadwick D., *J. Neurol. Neurosurg. Psychiatry* 1994; **57**: 264-277.
2. Gilham R.A., *Epilepsy Res.*, 1990; **7**: 219-225.



Give someone with epilepsy a future to look forward to

People with epilepsy have the same aspirations as anybody else. What they need is a treatment which allows them to fulfil their potential.

Whatever the type of epilepsy, Epilim Chrono can help. Effective both in generalized and partial seizures,¹ it is well tolerated (particularly with regard to cognitive function)², and offers patients the convenience of once-daily dosing.


It helps people with epilepsy get on with their lives today, and look forward to tomorrow.



Epilim[®] CHRONO[®]
Sodium Valproate Ph. Eur.
Valproic Acid Fr.P Controlled Release

**Once-daily management
for all forms of epilepsy**

Leadership isn't given. It's earned.



PROPERTY OF
MEDICAL LIBRARY
ST. BARNABAS HOSPITAL
183rd ST. & 3rd AVE
SPRING VALLEY, N. Y. 10457

PROZAC
fluoxetine

The World's No. 1
prescribed
antidepressant brand.

Further information is available on request from:
Dista Products Limited, Dextra Court, Chapel Hill,
Basingstoke, Hampshire RG21 5SY.

Legal Category: POM.

'PROZAC' is a Dista trade mark.

Date of preparation: March 1996

PZ733

